Review



alexa fluor 488 conjugated mouse anti human cd61  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bio-Rad alexa fluor 488 conjugated mouse anti human cd61
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Alexa Fluor 488 Conjugated Mouse Anti Human Cd61, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 36 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alexa fluor 488 conjugated mouse anti human cd61/product/Bio-Rad
    Average 93 stars, based on 36 article reviews
    alexa fluor 488 conjugated mouse anti human cd61 - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Preclinical Efficacy of a Hemostatic Agent in Overcoming Dual Antiplatelet Therapy"

    Article Title: Preclinical Efficacy of a Hemostatic Agent in Overcoming Dual Antiplatelet Therapy

    Journal: JACC: Basic to Translational Science

    doi: 10.1016/j.jacbts.2025.101356

    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human CD61 from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Figure Legend Snippet: In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human CD61 from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.

    Techniques Used: In Vitro, Fluorescence, Coagulation, Microscopy, Labeling, MANN-WHITNEY



    Similar Products

    alexa fluor 488 conjugated mouse anti human cd61  (Bio-Rad)
    93
    Bio-Rad alexa fluor 488 conjugated mouse anti human cd61
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Alexa Fluor 488 Conjugated Mouse Anti Human Cd61, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alexa fluor 488 conjugated mouse anti human cd61/product/Bio-Rad
    Average 93 stars, based on 1 article reviews
    alexa fluor 488 conjugated mouse anti human cd61 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    mouse anti-human monoclonal antibody conjugated allophycocyanin against β3-integrin (cd61  (Thermo Fisher)
    90
    Thermo Fisher mouse anti-human monoclonal antibody conjugated allophycocyanin against β3-integrin (cd61
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Mouse Anti Human Monoclonal Antibody Conjugated Allophycocyanin Against β3 Integrin (Cd61, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human monoclonal antibody conjugated allophycocyanin against β3-integrin (cd61/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    mouse anti-human monoclonal antibody conjugated allophycocyanin against β3-integrin (cd61 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse anti-human monoclonal antibody conjugated to allophycocyanin against β3-integrin (cd61)  (Thermo Fisher)
    90
    Thermo Fisher mouse anti-human monoclonal antibody conjugated to allophycocyanin against β3-integrin (cd61)
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Mouse Anti Human Monoclonal Antibody Conjugated To Allophycocyanin Against β3 Integrin (Cd61), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human monoclonal antibody conjugated to allophycocyanin against β3-integrin (cd61)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    mouse anti-human monoclonal antibody conjugated to allophycocyanin against β3-integrin (cd61) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pe mouse anti-human cd61 (vi-pl2  (Thermo Fisher)
    90
    Thermo Fisher pe mouse anti-human cd61 (vi-pl2
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Pe Mouse Anti Human Cd61 (Vi Pl2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe mouse anti-human cd61 (vi-pl2/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    pe mouse anti-human cd61 (vi-pl2 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse anti-human cd61  (Becton Dickinson)
    90
    Becton Dickinson mouse anti-human cd61
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Mouse Anti Human Cd61, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human cd61/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    mouse anti-human cd61 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse anti-human αvβ3 (cd51/cd61)-fitc  (Becton Dickinson)
    90
    Becton Dickinson mouse anti-human αvβ3 (cd51/cd61)-fitc
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Mouse Anti Human αvβ3 (Cd51/Cd61) Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human αvβ3 (cd51/cd61)-fitc/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    mouse anti-human αvβ3 (cd51/cd61)-fitc - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    phycoerythrin-conjugated mouse anti-human monoclonal antibodies to cd61 clone:vi-pl2  (Thermo Fisher)
    90
    Thermo Fisher phycoerythrin-conjugated mouse anti-human monoclonal antibodies to cd61 clone:vi-pl2
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Phycoerythrin Conjugated Mouse Anti Human Monoclonal Antibodies To Cd61 Clone:Vi Pl2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phycoerythrin-conjugated mouse anti-human monoclonal antibodies to cd61 clone:vi-pl2/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    phycoerythrin-conjugated mouse anti-human monoclonal antibodies to cd61 clone:vi-pl2 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    mouse anti-human cd61 percp-cy5.5  (Becton Dickinson)
    90
    Becton Dickinson mouse anti-human cd61 percp-cy5.5
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Mouse Anti Human Cd61 Percp Cy5.5, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human cd61 percp-cy5.5/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    mouse anti-human cd61 percp-cy5.5 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    monoclonal mouse anti-human cd61 antibody  (Agilent technologies)
    90
    Agilent technologies monoclonal mouse anti-human cd61 antibody
    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human <t>CD61</t> from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.
    Monoclonal Mouse Anti Human Cd61 Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal mouse anti-human cd61 antibody/product/Agilent technologies
    Average 90 stars, based on 1 article reviews
    monoclonal mouse anti-human cd61 antibody - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human CD61 from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.

    Journal: JACC: Basic to Translational Science

    Article Title: Preclinical Efficacy of a Hemostatic Agent in Overcoming Dual Antiplatelet Therapy

    doi: 10.1016/j.jacbts.2025.101356

    Figure Lengend Snippet: In Vitro Assessment of Platelet Reactivity by Aggregometry and MF (A) Percent maximal aggregation of platelets from patients on dual antiplatelet therapy (DAPT) (n = 27) in response to adenosine diphosphate (ADP) (20 μmol/L) and TRAP-6 (10 μmol/L). Results are compared with healthy donors (n = 15). (B) Mean fluorescence intensity (FI) (n = 8 clotting events per individual) of accumulated platelets from whole blood of healthy donors vs patients on DAPT using a PDMS (polydimethylsiloxane) device attached to a type I equine collagen–coated glass slide. Digital imagines were captured using an automated fluorescent microscope system ( t = 900 seconds). (C) Photomicrograph of a fabricated collagen-coated chip and deposition of platelets labeled with Alexa Fluor 488–conjugated mouse anti-human CD61 from healthy donors or DAPT-treated patients ( t = 900 seconds). (D) Mean platelet FI (n = 8 clotting events per individual) of accumulated platelets from WB of the same individuals from using collagen-coated chips and an integrated microfluidic (MF) device. (E) Maximal thrombus area (μm 2 ) occupied by calcein-labeled platelets from healthy donors vs patients (n = 10 mice per group, 10 individuals for each of the 2 groups, 3 arteriole injuries per mouse). The central box represents the values between the 10th and 90th percentiles, and the middle line is the mean. Statistical significance was determined using Mann-Whitney U test. ∗∗∗ P < 0.001 relative to healthy donors; ∗∗∗ P < 0.001 ADP relative to TRAP-6 for patients on DAPT.

    Article Snippet: The thrombin inhibitor H-D-Phe-Pro-Arg-chloromethylketone (PPACK), Alexa Fluor 488–conjugated mouse anti-human CD61, and Alexa Fluor 647–conjugated human fibrinogen were obtained from Bio-Rad and Thermo Fisher Scientific, respectively.

    Techniques: In Vitro, Fluorescence, Coagulation, Microscopy, Labeling, MANN-WHITNEY